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ubcapsular liver hematoma as a complication of an
typical hemolytic uremic syndrome
ematoma subcapsular hepático como complicación de síndrome
emolítico urémico atípico
ear Editor:
typical hemolytic uremic syndrome (aHUS) is a rare, life-
hreatening systemic inﬂammatory disease that presents
lassically with microangiopathic hemolytic anemia, throm-
ocytopenia and acute kidney injury.1 Extra renal manifesta-
ions are observed in 20% of patients.2
A 42-year-old woman with unremarkable past medical
istory presented in our hospital reporting a 6-day history
f headache, nausea and vomiting. Physical examination
howed hypertension (220/120mmHg), cutaneous pallor and
oderate lower limbs edema. Laboratory results revealed
nemia (hemoglobin 8.4 g/dl), thrombocytopenia (76,000/l),
evere azotemia (urea 16.9mmol/l, creatinine 448.8mol/l),
chistocytosis, a negative Coombs test, low blood haptoglobin
<0.07 g/L) and high lactate dehydrogenase levels (1234U/l).
enal ultrasonography was normal.
Blood pressure was hardly controlled with oral medication.
diagnosis of acute thrombotic microangiopathy (ATM) was
ade and daily plasma exchange (PEX) was started.
Investigations for secondary causes of ATM (pregnancy,
uto-immune disease, malignancy, drug-induced), infection-
nduced HUS and thrombotic thrombocytopenic purpura were
ormal. A presumptive diagnosis of aHUS was made and the
dministrative process of Eculizumab acquisition was initi-
ted.
On the 15th day of admission (D15), hemodialysis was
tarted due to progressive renal failure. All attempts to stop
EX resulted in increased hemolytic activity, forcing to main-
ain 3 sessions a week.
On the D72, after performing 44 PEX sessions, we were
till waiting for Eculizumab acquisition. Attending to clinical
nd analytical stability (Fig. 1), the patient was discharged
ome to continue hemodialysis and PEX three times a week
s an outpatient. Four days after discharge, she was admitted
n the emergency room with a 12-hour history of severe
ight upper quadrant pain and vomiting without history of
rauma. Laboratory results revealed stabilized hemoglobin
11.1 g/dl) and both normal platelet count (157,000/mm3) and
oagulation tests. Abdominal ultrasonography and Computed
omography scan showed a large subcapsular liver hematoma
hepatic bleeding related with heparin systemic anticoag-
ulation. Ultrasonography follow-up examinations revealed
almost unchanged size of hematoma.
Eculizumabwas started on the 10th day of admission in the
ICU (ICU D10) at a dose of 900mg per week for 4 weeks, fol-
lowed by subsequent doses of 1200mg every 2 weeks since the
5th week. Thereupon, platelet count increased and hemodial-
ysis was suspended on the ICU D35. She was transferred to the
Nephrology ward on the ICU D42 and was discharged home
three weeks later. The ﬁnal genetic workup was available only
after discharge anddetected a complement factorHhaplotype
H3 (−332T, c.184G, c.1204T, c.2016G, and c.2808T).
Currently, 8 months after eculizumab initiation, hema-
tologic remission persists, renal function remains stable
(ﬁgure 1) and last ultrasonography control showed a signif-
icant decrease in the size of hematoma – 3.94 cm×1.3 cm.
Alternate-week eculizumab infusions are still being contin-
ued.
Discussion: Complement system dysregulation in aHUS
induces thickening and inﬂammation of vascular wall, widen-
ing of subendothelial space and microvascular thrombosis.1
Renal microvasculature is predominantly affected but
extrarenal ischemic events, mainly involving central nervous
system, were also reported.2 Few hemorrhagic events were
also reported in patients with infection-induced HUS and in
secondary causes of ATM.3–5 Only three hemorrhagic events,
affecting pulmonary vasculature, were previously reported in
aHUS patients.6–8
SLH is a rare event that is mainly related with pregnancy-
induced hypertension (preeclampsia and HELLP syndrome)
and primary or metastatic liver tumors.9 Since HELLP syn-
drome is an ATM like aHUS,1 we speculate that SLH
pathogenesis might be similar in both diseases. In HELLP
syndrome, SLH is thought to be a consequence of hepatic
blood ﬂow obstruction due to ﬁbrin deposits within hepatic
sinusoids, resulting in periportal necrosis and intrahepatic
hemorrhage.10 Likewise, we believe vascular rupture in aHUS
might result from hepatic blood ﬂow obstruction secondary to
complement-induced microvascular thrombosis. Other pos-
sible contributors for bleeding diathesis in our patient were
uremic platelet dysfunction, difﬁcult-to-control hypertension
and heparinization during dialysis and PEX. It is importantSLH) (Fig. 2).
She was transferred to the Intensive Care Unit (ICU).
ttending to hemodynamic stability, a conservative approach
as attempted. PEX was suspended to prevent increased
DOI of original article:
ttp://dx.doi.org/10.1016/j.nefro.2015.03.003.to note that at the time of SLH diagnosis platelet count and
coagulation tests were normal.
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Fig. 1 – Clinical course: laboratory data and treatment. Blood transfusions were done when hemoglobin got around 8g/dl.
Plasma exchange consisted of one volume exchange with fresh frozen plasma. It was started on the second day of
admission and maintained until there was no evidence of hemolytic activity. Attempts at weaning plasma exchange were
unsuccessful due to increased hemolytic activity, forcing us to maintain 3 sessions a week until the diagnosis of the
subcapsular liver hematoma. We performed a total of 44 plasma exchange sessions. Hemodialysis was commenced on the
15th day of admission to manage her renal failure. Eculizumab was administered at a dose of 900mg per week for 4 weeks,
started on the 85th day after admission, followed by a dosage of 1200mg 1 week later and then a maintenance dose of
1200mg every 2 weeks. During the ﬁrst days of eculizumab usage, we could not use hemoglobin neither lactate
dehydrogenase to monitor hematologic response attending to the presence of the subcapsular liver hematoma that would
distort their interpretation. Hemodialysis was stopped 26 days after the ﬁrst infusion of eculizumab. Eculizumab is still
being continued on the maintenance schedule of 1200mg every 2 weeks. Reference range values: lactate dehydrogenase –
313–618U/l; platelet count – 150–400×103/mm3; hemoglobin – 12–16g/dl; plasma creatinine – 46–92mol/l.
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Fig. 2 – Abdominal computed tomography (A) and liver ultrasound (B) revealing a large subcapsular liver hematoma
(13.8 cm×3.9 cm) (arrows) causing compression of the underlying liver parenchyma. No source for the hemorrhage was
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2013-2514/© 2015 The Authors. Published by Elsevier España,
S.L.U. on behalf of Sociedad Española de Nefrología. Thisvident.
There is currently no documentation on the role of
culizumab to rescue aHUS-related hemorrhagic events since
one of the previously reported cases used it. However, we
elieve that the blockade of vascular injury achieved by
culizumab might have had some beneﬁcial effect.
Current treatment of aHUS relies on early onset of
culizumab based solely on clinical and laboratorial data.1
he decision to start eculizumab in our patient was made
ne week after presentation but the high cost of Eculizumab
imited its immediate availability and forced us to rely
n extensive and ineffective PEX while waiting for the
mmunoglobulin. Conversely, Eculizumab initiation allowed
mmediate hematologic complete remission and induced
emarkable renal recovery with discontinuation of dialysis
fter 3 months of replacement therapy.
In summary, our case highlights the ﬁrst report of a SLH
omplicating an aHUS and reinforces the importance of an
arlier intervention with Eculizumab to improve clinical out-
omes and to prevent the onset of severe complications.
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